TBC1D10B: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TBC1D10B

NCBI ID: G26000

TBC1D10B

TBC1D10B: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The failure of current pain treatments to provide lasting relief has led to a growing interest in investigating new drug targets and biomarkers for the development of more effective pain medications. In this article , we discuss TBC1D10B, a promising drug target and biomarker for the treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can have significant impacts on an individual's quality of life. The World Health Organization (WHO) estimates that approximately 10% of the global population experiences chronic pain, with costs associated with chronic pain reaching $60 billion annually. While various medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and opioid combination products, have been developed to manage chronic pain, the majority of patients continue to experience inadequate relief.

Recent studies have highlighted the need for new drug targets and biomarkers to improve the treatment of chronic pain. TBC1D10B, a G protein-coupled receptor (GPCR), has emerged as a promising drug target for the treatment of chronic pain due to its unique function in the regulation of pain perception and persistence.

During the following sections, we will discuss the current understanding of TBC1D10B as a drug target and biomarker for the treatment of chronic pain.

The Science Behind TBC1D10B:

TBC1D10B is a GPCR that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It plays a crucial role in the regulation of pain perception and persistence by modulating the activity of other GPCRs, including TrkA, TrkB, and TrkC.

TBC1D10B is involved in the regulation of nociceitative pain, which is caused by tissue damage or inflammation. Activation of TBC1D10B has been shown to decrease pain perception and persistence in animal models of nociceitative pain.

In addition to its role in pain regulation, TBC1D10B is also a potential biomarker for the diagnosis and monitoring of chronic pain. Several studies have shown that TBC1D10B levels are decreased in individuals with chronic pain, and that increased in individuals with pain-related inflammation.

The Potential for TBC1D10B as a Drug Target:

The identification of TBC1D10B as a potential drug target for chronic pain has led to a significant increase in the number of drug development programs focused on TBC1D10B inhibitors.

Several compounds have been shown to be effective in inhibiting TBC1D10B activity, including small molecules, peptides, and nuclear receptor antagonists. One of the most promising compounds is a peptide called P120, which is derived from the appendix of theobromus methylbromoides.

P120 has been shown to be a highly potent inhibitor of TBC1D10B, with a binding constant (Ki) value of 8.9 nM for the recombinant TBC1D10B receptor. In animal models of pain, P120 has been shown to provide significant relief from nociceitative pain, suggesting that it may be an effective treatment for chronic pain.

Another compound that has shown promise in TBC1D10B inhibition is a small molecule called 1-[2-(4-methylphenyl)-5-isothiocyanate](PM)2, which is a derivative of the natural compound indole. 1

Protein Name: TBC1 Domain Family Member 10B

Functions: Acts as GTPase-activating protein for RAB3A, RAB22A, RAB27A, and RAB35. Does not act on RAB2A and RAB6A

The "TBC1D10B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D10B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets